ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia

This study is testing a combination of a stem cell transplant (ASCT), CAR-T cell therapy targeting a protein called BCMA, and a maintenance drug (BiTE) targeting another protein called GPRC5D, in newly diagnosed patients with plasma cell leukemia — a rare and aggressive blood cancer. **You may be eligible if:** - You are between 18 and 70 years old - You have newly diagnosed plasma cell leukemia - Your cancer has detectable levels of disease in blood or urine tests - Your cancer cells test positive for BCMA and GPRC5D proteins - Your organs (liver, kidneys) are functioning well enough - You are healthy enough to undergo a stem cell transplant **You may NOT be eligible if:** - You have already received treatment for this condition - Your organ function does not meet study requirements - You are not fit enough for high-dose chemotherapy and transplant Talk to your doctor to see if this trial is right for you.